Levofloxacin pharmacokinetics/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis

Levofloxacin pharmacokinetics/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis

<p><strong>Background</strong> Levofloxacin is used for the treatment of multidrug-resistant tuberculosis; however the optimal dose is unknown.</p> <p><strong>Methods</strong> We used the hollow fiber system model of tuberculosis (HFS-TB) to identify 0–24 h...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Deshpande, D, Pasipanodya, JG, Mpagama, SG, Bendet, P, Srivastava, S, Koeuth, T, Lee, PS, Bhavnani, SM, Ambrose, PG, Thwaites, G, Heysell, SK, Gumbo, T
Formatua: Journal article
Hizkuntza:English
Argitaratua: Oxford University Press 2018
Gaiak:
lung
artificial intelligence
mutation
minimum inhibitory concentration result
minimum inhibitory concentration measurement
pharmacokinetics
pharmacodynamics
exposure
pulmonary tuberculosis
tuberculosis
levofloxacin
moxifloxacin
tuberculous meningitis
multidrug-resistant tuberculosis
probit trial

Antzeko izenburuak